Company intelligence / Profile preview

Kine Team

Gangnam-gu, South Koreamedium.com ↗

Ownership: Private
Development stage: Other

Overview

Kine Sciences is a clinical-stage biopharmaceutical company developing synthetic peptide drugs that modulate immune responses, with a focus on chronic neuroinflammatory and autoimmune diseases. Its lead asset, KINE‑101, is in Phase 1b/2a trials for CIDP after successful US Phase 1 results. The pipeline includes six assets across nineteen indications, including Alzheimer’s disease and rheumatoid arthritis. Early clinical data suggest potential as a disease-modifying therapy by activating regulatory T cells.

Therapeutic areas: GastroenterologyImmunologyNeurologyOncology
Modalities: Synthetic peptideSmall molecule drugChemical drugs
Industry: Biotech

Beyond the preview

Go deeper on Kine Team.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kine Team.

Explore the full profile